About Context Therapeutics Inc.
https://www.contexttherapeutics.comContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.
CEO
Martin A. Lehr
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BIOIMPACT CAPITAL LLC
Shares:14.71M
Value:$23.09M
AVIDITY PARTNERS MANAGEMENT LP
Shares:8.98M
Value:$14.1M
DEEP TRACK CAPITAL, LP
Shares:7.42M
Value:$11.65M
Summary
Showing Top 3 of 44
About Context Therapeutics Inc.
https://www.contexttherapeutics.comContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.61M ▲ | $-9.69M ▼ | 0% | $-0.1 ▼ | $-9.69M ▲ |
| Q2-2025 | $0 | $9.76M ▲ | $-8.83M ▼ | 0% | $-0.09 ▼ | $-9.75M ▼ |
| Q1-2025 | $0 | $5.53M ▲ | $-4.58M ▼ | 0% | $-0.05 ▲ | $-5.53M ▼ |
| Q4-2024 | $0 | $4.31M ▼ | $-3.34M ▲ | 0% | $-0.06 ▲ | $-4.31M ▲ |
| Q3-2024 | $0 | $18.7M | $-17.46M | 0% | $-0.22 | $-18.7M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $76.94M ▼ | $79.23M ▼ | $6.06M ▲ | $73.17M ▼ |
| Q2-2025 | $83.52M ▼ | $87.15M ▼ | $4.61M ▲ | $82.54M ▼ |
| Q1-2025 | $89.35M ▼ | $92.97M ▼ | $1.98M ▼ | $90.98M ▼ |
| Q4-2024 | $94.43M ▲ | $98.13M ▲ | $2.86M ▲ | $95.27M ▲ |
| Q3-2024 | $84.8M | $86.33M | $2.47M | $83.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.69M ▼ | $-6.58M ▼ | $0 | $0 | $-6.58M ▼ | $-6.58M ▼ |
| Q2-2025 | $-8.83M ▼ | $-5.84M ▼ | $0 ▲ | $0 ▲ | $-5.84M ▼ | $-5.84M ▼ |
| Q1-2025 | $-4.58M ▼ | $-5.03M ▼ | $-33.95K ▼ | $-15.27K ▼ | $-5.08M ▼ | $-5.06M ▼ |
| Q4-2024 | $-3.34M ▲ | $-4.91M ▼ | $0 ▲ | $14.54M ▲ | $9.63M ▲ | $-4.91M ▼ |
| Q3-2024 | $-17.46M | $-1.93M | $-14.76M | $-44.63K | $-16.73M | $-1.94M |
CEO
Martin A. Lehr
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BIOIMPACT CAPITAL LLC
Shares:14.71M
Value:$23.09M
AVIDITY PARTNERS MANAGEMENT LP
Shares:8.98M
Value:$14.1M
DEEP TRACK CAPITAL, LP
Shares:7.42M
Value:$11.65M
Summary
Showing Top 3 of 44